Company: BIAF
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023405
Chunk: 3

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 8
Chunk 3
---
 income (expense), net 
     (2,755,056) 
     (24,417) 
     (4,295,882) 
     (54,392)

    Net loss before provision for income tax expense 
     (5,047,902) 
     (1,998,281) 
     (11,731,427) 
     (6,061,284)

    Provision for income tax expense 
     3,182  
     2,559  
     40,861  
     11,650 

    Net loss 
    $(5,051,084) 
    $(2,000,840) 
    $(11,772,288) 
    $(6,072,934)

    Net loss per common share, basic and diluted(2) 
    $(4.74) 
    $(4.84) 
    $(7.55) 
    $(16.22)

    Weighted average common shares outstanding(2) 
     1,066,350  
     412,936  
     804,604  
     374,445 

(2)The
                                            values of Common Stock and paid-in capital, as well as the number of shares issued and outstanding,
                                            have been retroactively adjusted in order to give effect to the Company’s 1-for-30
                                            reverse stock split.

The
accompanying notes are an integral part of these unaudited consolidated financial statements

6

bioAffinity
Technologies, Inc.

Unaudited
Consolidated Statements of Changes in Stockholders’ Equity

    Shares  
    Amount  
    Shares  
    Amount(3)  
    Capital(3)  
    Deficit  
    Equity 

    For the Nine Months Ended September 30, 2025 

    Preferred Stock  
    Common Stock(3)  
    Additional  Paid-in  
    Accumulated  
    Stockholders’ 

    Shares  
    Amount  
    Shares  
    Amount  
    Capital(3)  
    Deficit  
    Equity 

    Balance at December 31, 2024 
     —  
    $—  
     507,520  
    $3,553  
    $56,242,793  
    $(53,644,310) 
    $